East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Infliximab
Remsima
Not routinely available
NICE (TA329 (SMC 1006/14))
01/07/2019

Indication

Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate; adult pa...

Rheumatoid arthritis: in combination with methotrexate, for the reduction of signs and symptoms as well as improvement in physical function in: adult patients with active disease when the response to disease-modifying antirheumatic drugs (DMARDs), including methotrexate has been inadequate; adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines

Formulation

100mg powder for concentrate for solution for infusion

Comments

February 2015 - NICE MTA Advice: SMC Advice 1006/14 is superseded by NICE TA329. September 2015 - Included on the LJF, for Specialist Use only, for the indication in question. July 2019 (as per LJF) - Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.

Link to Advice

TA329 (SMC 1006/14)

Advice Published

25/02/2015